Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
THOMAS PAUL reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Paul Thomas reported receiving a grant of 5,579 restricted stock units as equity compensation for his Board service. Each unit represents one share of common stock and the award is valued at $235,000 as of the grant date. The restricted stock units vest on June 24, 2027, the one-year anniversary of the grant date, and Thomas’s directly held derivative position from this grant totals 5,579 units after the transaction.
Axogen, Inc. director Joseph A. Tyndall received a grant of 4,392 restricted stock units as equity compensation for his service on the Board of Directors. Each unit represents a contingent right to receive one share of Axogen common stock.
The annual equity grant is based on a $185,000 valuation as of the grant date and will vest on June 24, 2027, the one-year anniversary of the grant. Following this award, Tyndall holds 4,392 restricted stock units directly, reflecting a routine compensation-related acquisition rather than an open-market purchase.
Weiler Kathy Johnson reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Kathy Johnson Weiler received a grant of 4,392 restricted stock units as annual equity compensation for her service on the board. Each unit represents a contingent right to receive one share of Axogen common stock. The grant is valued at $185,000 as of the grant date and will vest on June 24, 2027, the one-year anniversary of the grant date. Following this award, she holds 4,392 restricted stock units directly.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Wendell Amy McBride received an annual equity grant of restricted stock units for service on the Board of Directors. The award covers 4,392 restricted stock units, each representing a right to receive one share of common stock, based on a $185,000 valuation as of the grant date. These units vest on June 24, 2027, the one-year anniversary of the grant date, and reflect compensation rather than an open‑market share purchase.
Axogen, Inc. reported the results of its 2026 annual meeting of shareholders. A total of 45,364,808 shares were present or represented by proxy, out of 53,177,824 shares outstanding and entitled to vote as of April 24, 2026, indicating strong participation.
Shareholders elected eight directors to serve one-year terms until the 2027 annual meeting, with each nominee receiving a substantial majority of votes cast. Deloitte & Touche LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders also approved, on an advisory and non-binding basis, the compensation of Axogen’s named executive officers, with 38,606,031 votes in favor versus 1,419,784 against. Overall, the voting results reflect broad shareholder support for the board slate, auditor selection, and executive pay program.
Axogen, Inc. director Alan M. Levine reported the vesting of restricted stock units and corresponding acquisition of common shares as part of his annual board compensation. On June 19, 2026, 14,150 restricted stock units vested, converting into 14,150 shares of Axogen common stock at no cash exercise price.
Each unit represented the right to receive one share, based on an equity grant valued at $150,000 as of the grant date. After this vesting and conversion, Levine directly holds 50,893 shares of Axogen common stock, reflecting a compensation-related, non‑market transaction rather than an open‑market purchase or sale.
Axogen, Inc. director Kathy Johnson Weiler acquired 14,150 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 14,150 restricted stock units converted into an equal number of common shares at a price of $0.00 per share as part of her annual equity compensation for Board service, which was originally valued at $150,000 on the grant date. Following the vesting and conversion, she directly holds 14,150 shares of Axogen common stock, and the reported restricted stock units from this grant are fully settled.
Axogen, Inc. director Wendell Amy McBride acquired 14,150 shares of common stock through the vesting and conversion of restricted stock units on June 19, 2026. These RSUs were an annual equity grant for Board service, valued at $150,000 as of the grant date.
Each vested unit converted into one share of Axogen common stock, increasing McBride’s directly held position to 107,976 shares after the transaction. This is a compensation-related derivative exercise, not an open-market purchase or sale.
Axogen, Inc. director THOMAS PAUL acquired 18,867 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 18,867 restricted stock units converted into an equal number of common shares as they vested, reflecting an annual equity grant for service on the Board.
The equity grant was based on a $200,000 valuation as of the original grant date and vested on the one-year anniversary of that date. Following this vesting and conversion, Paul directly holds 32,395 shares of Axogen common stock.
TYNDALL JOSEPH A. reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Joseph A. Tyndall reported the vesting of 14,150 restricted stock units on June 19, 2026, which were settled into 14,150 shares of common stock. Each restricted stock unit represented a right to receive one share upon vesting, reflecting an annual equity grant for board service valued at $150,000 on the grant date. This filing shows a compensation-related equity award vesting, not an open-market stock purchase or sale.